Annals ofAntibiotics

Volume: 9 - Number: 84 - October 15, 2011

Outstanding

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

Global spread of carbapenem-resistant Acinetobacter baumannii

Reducing antimicrobial resistance in the community by restricting prescribing: can it be done?

Leading articles

Reducing antimicrobial resistance in the community by restricting prescribing: can it be done?

Harmonization of antimicrobial susceptibility testing breakpoints in Europe: implications for reporting intermediate susceptibility

Original Research

Genetic analysis of extensively drug-resistant Mycobacterium tuberculosis strains in Lisbon, Portugal

Novel role of Acinetobacter baumannii RND efflux transporters in mediating decreased susceptibility to biocides

Global spread of carbapenem-resistant Acinetobacter baumannii

Smaqnr, a new chromosome-encoded quinolone resistance determinant in Serratia marcescens

Plasmid pKpQIL encoding KPC-3 and TEM-1 confers carbapenem resistance in an extremely drug-resistant epidemic Klebsiella pneumoniae strain

Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results

Resistance development profiling of piperacillin in combination with the novel ?-lactamase inhibitor BLI-490

In vitro antimicrobial activity of silver-processed catheters for neurosurgery

Activity of the siderophore monobactam BAL30072 against multiresistant non-fermenters

In vitro activity of antifungal combinations against Candida albicans biofilms

DAS181, a sialidase fusion protein, protects human airway epithelium against influenza virus infection: an in vitro pharmacodynamic analysis

Antifungal activity of Leptospermum petersonii oil volatiles against Aspergillus spp. in vitro and in vivo

Reviews

In vitro pharmacodynamic models to determine the effect of antibacterial drugs

Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)

Resistance profile of the new nucleoside reverse transcriptase inhibitor apricitabine

New therapeutic strategies for raltegravir